Strategic objectives

• Development of a therapeutic strategy based on ophthalmic pharmacology.
• Evaluate the therapeutic effect of pharmacological agents, neuroprotectors and neuromodulators included in PLGA particles.
• Development of neuroprotective agents in retinal neurodegenerations.

Research lines

• Evaluation of the presence of light responses in blind photoswitch-injected mice using electrophysiological registry techniques and visual behaviour evaluation techniques.
• Preparation and characterisation of PLGA particles loaded with therapeutic agents for application in retinal cellular degeneration, with the study of the molecular release and PLGA particle injection, as well as studies of functional effectiveness.
• Experimental models of glaucoma and mechanisms of ganglion cell neuroprotection from retina.
• Protective role of physical exercise in neurodegenerative diseases.